Abstract
Many cancer cells have high expression of ornithine decarboxylase (ODC) and there is a concerted effort to seek new inhibitors of this enzyme. The aim of the study was to initially characterize the inhibition properties, then to evaluate the cytotoxicity/antiproliferative cell based activity of N-chloroacetyl-l-ornithine (NCAO) on three human cancer cell lines. Results showed NCAO to be a reversible competitive ODC inhibitor (Ki=59μM) with cytotoxic and antiproliferative effects, which were concentration- and time-dependent. The EC50,72h of NCAO was 15.8, 17.5 and 10.1μM for HeLa, MCF-7 and HepG2 cells, respectively. NCAO at 500μM completely inhibited growth of all cancer cells at 48h treatment, with almost no effect on normal cells. Putrescine reversed NCAO effects on MCF-7 and HeLa cells, indicating that this antiproliferative activity is due to ODC inhibition.
Author supplied keywords
Cite
CITATION STYLE
Medina-Enríquez, M. M., Alcántara-Farfán, V., Aguilar-Faisal, L., Trujillo-Ferrara, J. G., Rodríguez-Páez, L., & Vargas-Ramírez, A. L. (2015). N-ω-chloroacetyl-l-ornithine, a new competitive inhibitor of ornithine decarboxylase, induces selective growth inhibition and cytotoxicity on human cancer cells versus normal cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 30(3), 345–353. https://doi.org/10.3109/14756366.2014.926342
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.